On this basis, the gut metabolomic profile was characterized in 11 non-small cell lung cancer (NSCLC) patients treated with nivolumab anti-PD-1 therapy, which showed that 2-pentanone and tridecane were significantly associated with early progression, while SCFAs, lysine and nicotinic acid were significantly associated with long-term beneficial effects [140]. Here, PDCD1 is linked to non-small cell lung carcinoma.